Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Liabilities and Shareholders Equity (2022 - 2025)

Envoy Medical's Liabilities and Shareholders Equity history spans 4 years, with the latest figure at $8.2 million for Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity fell 12.94% year-over-year to $8.2 million; the TTM value through Sep 2025 reached $40.0 million, up 21.65%, while the annual FY2024 figure was $11.5 million, 39.5% up from the prior year.
  • Liabilities and Shareholders Equity for Q3 2025 was $8.2 million at Envoy Medical, down from $9.9 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $427.8 million in Q3 2022 and bottomed at $2.6 million in Q4 2022.
  • The 4-year median for Liabilities and Shareholders Equity is $10.4 million (2025), against an average of $97.9 million.
  • The largest YoY upside for Liabilities and Shareholders Equity was 223.59% in 2023 against a maximum downside of 95.04% in 2023.
  • A 4-year view of Liabilities and Shareholders Equity shows it stood at $2.6 million in 2022, then surged by 223.59% to $8.3 million in 2023, then skyrocketed by 39.5% to $11.5 million in 2024, then fell by 29.1% to $8.2 million in 2025.
  • Per Business Quant, the three most recent readings for COCH's Liabilities and Shareholders Equity are $8.2 million (Q3 2025), $9.9 million (Q2 2025), and $10.4 million (Q1 2025).